Search Result

Results for "

MDA-MB-468

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA synthetase (1) ADC Antibody (1) ADC Payload (4) Akt (5) Annexin A (1) Antifolate (2) Apoptosis (38) Aryl Hydrocarbon Receptor (3) ATM/ATR (2) Autophagy (6) Bcl-2 Family (1) Bcr-Abl (2) c-Met/HGFR (1) c-Myc (2) Calmodulin (1) CaMK (1) Carbonic Anhydrase (3) Casein Kinase (1) Caspase (4) Cathepsin (1) CDK (18) ClpP (1) Cytochrome P450 (3) Deubiquitinase (1) DNA Methyltransferase (1) DNA/RNA Synthesis (6) Drug Intermediate (1) Drug-Linker Conjugates for ADC (5) DYRK (2) Early 2 Factor (E2F) (1) EGFR (3) Epigenetic Reader Domain (4) ERK (4) FAK (1) Farnesyl Transferase (1) Fatty Acid Synthase (FASN) (1) Ferroptosis (2) FKBP (1) FLT3 (1) Fluorescent Dye (2) Fungal (1) Gli (1) Glutathione Peroxidase (2) GSK-3 (2) Hedgehog (1) Histone Methyltransferase (3) HSP (7) HuR (1) HyT (1) Integrin (1) JAK (3) JNK (1) LPL Receptor (1) MASTL (1) MEK (1) MELK (2) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) MMP (2) Mps1 (1) mTOR (3) Necroptosis (1) NF-κB (2) p38 MAPK (2) p62 (1) Parasite (3) PARP (12) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (4) Phosphoglycerate Dehydrogenase (PHGDH) (3) Phospholipase (1) PI3K (3) Pim (2) PIN1 (3) Polo-like Kinase (PLK) (3) PPAR (1) PROTACs (15) Protease Activated Receptor (PAR) (1) Proteasome (2) Pyroptosis (1) Quinone Reductase (1) RAD51 (1) Radionuclide-Drug Conjugates (RDCs) (1) Ras (1) Reactive Oxygen Species (ROS) (4) Reference Standards (4) RIP kinase (2) SHP2 (2) Smo (1) Src (5) SRPK (1) STAT (16) Topoisomerase (2) Transmembrane Glycoprotein (2) TrxR (1) Tyrosinase (1) VEGFR (1) Wnt (1) YTHDF (1) β-catenin (1) γ-secretase (1)
By Research Areas:	Cancer (139) Cardiovascular Disease (2) Infection (6) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (2)
Click Chemistry:	PROTAC Synthesis (1) Azide (1) Alkynes (4)

141

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-11038

Zelavespib Maximum Cited Publications 13 Publications Verification PU-H71	HSP	Cancer
Zelavespib (PU-H71) is a potent Hsp90 inhibitor, with an IC₅₀ of 51 nM in MDA-MB-468 cells.

HY-139361

Sulfopin 3 Publications Verification PIN1-3	PIN1	Cancer
Sulfopin (PIN1-3) is a highly selective covalent inhibitor of Pin1 with an apparent K_i of 17 nM. Sulfopin blocks Myc-driven tumors in vivo. The peptidyl-prolyl isomerase, Pin1, is exploited in cancer to activate oncogenes and inactivate tumor suppressors .

HY-79256

MMAF-OMe 1 Publications Verification Monomethyl auristatin F methyl ester	ADC Payload	Cancer
MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC₅₀s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 ^-) cell lines, respectively.

HY-153992

STAT6-IN-3 1 Publications Verification	STAT	Inflammation/Immunology
STAT6-IN-3 is a phosphopeptide mimic targeting the SH2 domain of STAT6 and has a high affinity for STAT6 (IC₅₀: 0.04 μM). STAT6-IN-3 can be used in the research of inflammation such as asthma .

HY-10395

PD173955 1 Publications Verification	Bcr-Abl Src	Cancer
PD173955 is an orally active inhibitor of Src (IC₅₀= 22 nM), Yes, Abl, ATP and MAP kinases. PD173955 can effectively prevent the mitotic process and has anticancer activity .

HY-N2959

Brevilin A 5 Publications Verification	JAK STAT Apoptosis Autophagy	Cancer
Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC₅₀=?10.6 μM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy .

HY-12807

FIPI 5 Publications Verification 5-Fluoro-2-indolyl deschlorohalopemide	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .

HY-147098

dTAG-47 1 Publications Verification	PROTACs FKBP	Cancer
dTAG-47 is a FKBP12F36V PROTAC degrader. dTAG-47 efficiently degrades FKBP12F36V-MELK(sg3R) in MELK ^⁻/⁻ MDA-MB-468-FKBP12F36V-MELK(sg3R) cells. dTAG-47 can be used for the research of basal-like breast cancers (BBC). (Pink: FKBP12F36V ligand (HY-114420), Blue: CRBN Ligand (HY-W087383), Black: Linker (HY-42773), E3 ligase ligand-linker conjugate (HY-175952)) .

HY-101982

Lys-SMCC-DM1 1 Publications Verification Lys-Nε-MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a HER2-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer .

HY-112338

C188 CPD188	STAT Apoptosis	Cancer
C188 (CPD188) is a STAT3 inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC₅₀ of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC₅₀s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .

HY-161456

PHGDH-IN-5	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-5 (Compound B12) is a covalen inhibitor of PHGDH with an IC₅₀ value of 0.29 μM. PHGDH-IN-5 can inhibit cell proliferation in cancer cell lines overexpressing PHGDH. PHGDH-IN-5 can reduce the production of serine derived from glucose in MDA-MB-468 cells .

HY-N0364

Falcarindiol 3 Publications Verification	Apoptosis Autophagy PPAR	Infection Metabolic Disease Inflammation/Immunology Cancer
Falcarindiol, an orally active polyacetylenic oxylipin, activates PPARγ and increases the expression of the cholesterol transporter ABCA1 in cells. Falcarindiol induces apoptosis and autophagy. Falcarindiol has anti-inflammatory, antifungal, anticancer and antidiabetic properties . Falcarindiol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-148570

PHGDH-IN-3 1 Publications Verification	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC₅₀ value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer .

HY-103692

STX-0119 2 Publications Verification	STAT	Cancer
STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC₅₀ of 74 μM .

HY-162037

CDDD11-8	CDK FLT3	Cancer
CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with K_i values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation .

HY-115997

PROTAC HSP90 degrader BP3	PROTACs HSP	Cancer
PROTAC HSP90 degrader BP3 is a potent and selective degradation of HSP90 in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain degradation effect on HSP90 protein in MCF-7 cells (DC₅₀=0.99 μM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell . PROTAC HSP90 degrader BP3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-155113

PROTAC Hsp90α degrader 1	PROTACs HSP	Cancer
PROTAC Hsp90α degrader 1 (Compound X10g) is a selective PROTAC Hsp90α degrader. PROTAC Hsp90α degrader 1 can be used for breast cancer research. PROTAC Hsp90α degrader 1 inhibits the proliferation of MDA-MB-231, MDA-MB-468, MCF-7, MX-1 cells with IC₅₀s of 51.48 μM, 16.46 μM, 8.93 μM, 11.95 μM respectively .

HY-129800

CGP78850 2 Publications Verification	ERK	Cancer
CGP78850 is a potent and selective competitor of Grb2 SH2-phosphopeptide interactions. CGP78850 can be used for the research of cancer .

HY-156515

MC-GGFG-(7ethanol-10NH2-11F-Camptothecin)	Drug-Linker Conjugates for ADC	Cancer
MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is a drug-linker conjugate for ADC, formed by conjugation of 7ethanol-10NH2-11F-Camptothecin (HY-156517) with the protease-cleavable MC-GGFG linker. MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is applicable for cancer research .

HY-149209

LL-K8-22	PROTACs CDK STAT Early 2 Factor (E2F)	Cancer
LL-K8-22 is a potent, selective and durable PROTAC CDK8-cyclin C dual degrader, with DC₅₀ values of 2.52 and 2.64 μM, respectively. LL-K8-22 also suppresses STAT1 Ser 727 phosphorylation. LL-K8-22 inhibits E2F- and MYC-driven carcinogenic transcriptional programs. LL-K8-22 can be used for triplenegative breast cancer (TNBC) research. (Pink: Ligand for target protein (HY-168683); Black: Linker (HY-Y0340); Blue: Ligand for E3 ligase (HY-N2427)) .

HY-11038B

Zelavespib hydrochloride Maximum Cited Publications 13 Publications Verification PU-H71 hydrochloride	HSP	Cancer
Zelavespib (PU-H71) hydrochloride is a potent Hsp90 inhibitor, with an IC₅₀ of 51 nM in MDA-MB-468 cells.

HY-155787

SHR5428	CDK	Cancer
SHR5428 is a potent, orally active, selective and noncovalent inhibitor of CDK7 with highly potent CDK7 enzymatic activity (IC₅₀=2.3 nM). SHR5428 inhibits triple negative breast cancer cellular activity on MDA-MB-468 cell (IC₅₀=6.6 nM) .

HY-N8187

Eupalinolide O	Apoptosis	Cancer
Eupalinolide O is a sesquiterpene lactone with anticancer activities. Eupalinolide O induces cell apoptosis in human MDA-MB-468 breast cancer cells .

HY-11038D

Zelavespib formic Maximum Cited Publications 13 Publications Verification PU-H71 formic	HSP	Cancer
Zelavespib formic (PU-H71 formic) is a potent Hsp90 inhibitor with an IC₅₀ value of 51 nM for Hsp90 in MDA-MB-468 cells .

HY-119653

AZ9482	PARP	Cancer
AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-132135

(1E)-CFI-400437 dihydrochloride	Polo-like Kinase (PLK)	Cancer
(1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC₅₀= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, KDR and FLT-3 with IC₅₀s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity .

HY-133120A

INY-03-041 trihydrochloride 1 Publications Verification	PROTACs Akt	Cancer
INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003). INY-03-041 trihydrochloride inhibits AKT1, AKT2 and AKT3 with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively .

HY-122665

HTH-01-091	MELK DYRK Pim mTOR CDK GSK-3 RIP kinase	Cancer
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be uesd for breast cancer research .

HY-115605

CN009543V	EGFR p38 MAPK ERK Phosphatase	Cancer
CN009543V is an epidermal growth factor receptor (EGFR) agonist. CN009543V enhances tyrosine phosphorylation of EGFR at Tyr1068 and Tyr1173, thereby activating the MAPK/ERK cascade. CN009543V inhibits the activity of PTP-1B in MDA MB468 cells. CN009543V can be used in cancer research .

HY-158170

CDK7-IN-28	CDK	Cancer
CDK7-IN-28 (CDK7-1276) is a potent CDK7 inhibitor(IC₅₀＜5 nM). CDK7-IN-28 can inhibit proliferation of MDA-MB-468 cell line by blocking cell cycle and inhibiting DNA replication .

HY-173002

MS9024	DNA Methyltransferase	Cancer
MS9024 is the degrader for DNA methyltransferase 1 that degrades DNMT1 in cell HCT116 through the ubiquitin-proteasome pathway with a DC₅₀ of 35 nM (DC₅₀ in MDA-MB-468 and H1299 is 254 nM and 101 nM). MS9024 also inhibits DNMT1 with an IC₅₀ of 0.43 μM .

HY-143293

VEGFR-IN-3	VEGFR Apoptosis	Cancer
VEGFR-IN-3 (compound 3f) is a VEGFR inhibitor. VEGFR-IN-3 inhibits OVCAR-4 and MDA-MB-468 cancer cells growth with IC₅₀s of 0.29 and 0.35 μM, respectively. VEGFR-IN-3 can be used for the research of cancer .

HY-145860

PHGDH-IN-2	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-2 is a potent and NAD ⁺ competitive PHGDH inhibitor with an IC₅₀ of 5.2 µM. PHGDH-IN-2 inhibits the serine synthetic pathway in MDA-MB-468 cells. PHGDH-IN-2 inhibits the growth of PHGDH-dependent cancer cells .

HY-176549

(Rac)-IBR120	RAD51	Cancer
(Rac)-IBR120 is the racemate of IBR120 (HY-176549A). IBR120 is a RAD51 inhibitor that has significant growth inhibition activity against MDA-MB-468 cells. (Rac)-IBR120 can be used for the research of difficult-to-treat cancers like triple negative breast cancer .

HY-P990859

Anti-CD44 Antibody (Hermes-1) 1 Publications Verification	Transmembrane Glycoprotein	Others
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a κ chimeric antibody, targeting to human CD44. Anti-CD44 Antibody (Hermes-1) blocks the binding of hyaluronan to CD44. Anti-CD44 Antibody (Hermes-1) restores (Platelet-derived Growth Factor-BB)-induced β-receptor activation and motility in fibroblasts. Anti-CD44 Antibody (Hermes-1) causes partial loss of the anti-aging effect of hyaluronic .

HY-155339

Anticancer agent 168	Apoptosis DNA/RNA Synthesis	Cancer
Anticancer agent 168 (compound d16) is a inhibitor of DNA2. Anticancer agent 168 induces apoptosis and cell-cycle arrest mainly at S-phase, and exhibits anticancer activities and overcomes chemotherapy resistance in mutp53-bearing cancers .

HY-145260

BRD4/CK2-IN-1	Epigenetic Reader Domain Casein Kinase Apoptosis Autophagy	Cancer
BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), with IC₅₀s of 180 nM and 230 nM for BRD4 and CK2, respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy-associated cell death in triple-negative breast cancer (TNBC)

HY-120234

Z-LLNle-CHO Z-Leu-Leu-Nle-CHO; GSII	γ-secretase Proteasome Apoptosis	Cancer
Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia .

HY-172957

JNN-5	JAK	Cancer
JNN-5 is a potent and selective JAK2 inhibitor with an IC₅₀ of 0.41 nM. JNN-5 shows strong antiproliferative activities in the TNBC cell lines (MDA-MB-468, MDA-MB-213, HCC70, MDA-MB-157) .

HY-159990

GPX4-IN-15	Glutathione Peroxidase	Cancer
GPX4-IN-15 (Compound C1) is an inhibitor for GPX4, that inhibits 19.8% GPX4 at 1 μM. GPX4-IN-15 inhibits the proliferation of cancer cell MDA-MB-468, BT-549 and MDA-MB-231 with IC₅₀ of 0.86, 0.96 and 0.48 μM .

HY-174828

ATR/PARP1-IN-1	PARP ATM/ATR Apoptosis	Cancer
ATR/PARP1-IN-1 is a potent ATR and PARP1 dual inhibitor with IC₅₀s of 17.3 nM and 0.38 nM, respectively. ATR/PARP1-IN-1 effectively reduces cell viability, induces apoptosis and DNA damage. ATR/PARP1-IN-1 significantly impairs triple-negative breast cancer (TNBC) colony formation, migration, and invasion. ATR/PARP1-IN-1 suppresses tumor growth effectively in MDA-MB-468 xenografted mice, with no significant body weight change .

HY-W338764

AHR agonist 3	Apoptosis Aryl Hydrocarbon Receptor	Cancer
AHR agonist 3 is an aryl hydrocarbon receptor (AhR) agonist, that can induces cell cycle arrest or apoptosis via activation of tumor-suppressive transcriptional programs. AHR agonist 3 inhibits triple-negative breast cancer (TNBC) stem cell growth via AhR while exhibits minimal cytotoxicity against normal human primary cells and can be used for cancer research .

HY-163709

PROTAC FAK degrader 2	PROTACs FAK	Cancer
PROTAC FAK degrader 2 (Compound F2) is a PROTAC degrader for focal adhesion kinase (FAK), with DC₅₀ of 27.72 and 60.1 nM, for total FAK and phosphorylated p-FAK. PROTAC FAK degrader 2 inhibits cell viability of cancer cells 4T1, MDA-MB-231, MDA-MB-468 and MDA-MB-435, with IC₅₀s of 0.73-5.84 μM. PROTAC FAK degrader 2 reverses the multidrug resistance (MDR) through inhibition of AKT and ERK signaling pathway. PROTAC FAK degrader 2 exhibits antitumor efficacy in HCT/8 xenograft mouse model. (Pink: ligand for target protein Ifebemtinib (HY-122844); Black: linker (HY-Y0681); Blue: ligand for E3 ligase Thalidomide (HY-14658))

HY-101447

SI-2 EPH 116	Src Apoptosis	Cancer
SI-2 (EPH 116) is an inhibitor for steroid receptor coactivator-3 (SRC-3), which reduces the transcriptional activity and protein concentration of SRC-3 in cells, exhibits cytotoxicity in cancer cell, inhibits migration of MDA-MB-468, induces apoptosis of MDA-MB-468. SI-2 inhibits the tumor growth in mouse models, without significant toxicity for heart and other major organs (20 mg/kg) .

HY-10062

AZD3409 EBP-921	Akt Farnesyl Transferase	Cancer
AZD3409 is a prenyl inhibitor that exhibits inhibitory activity against both farnesyl transferase and geranylgeranyl transferase I. AZD3409 inhibits the growth of breast cancer cells, with IC₅₀s of 220 nM (MDA-MB-468), 180 nM (MDA-MB-361), and 290 nM (SK-Br-3). AZD3409 significantly reduces the activation level of AKT in breast cancer cell lines. AZD3409 induces G0/G1 phase arrest in MDA-MB-468 cells, causes G2/M phase arrest in MDA-MB-361 cells. AZD3409 can be used for the study of breast cancer .

HY-P10760

PhAc-ALGP-Dox	Peptide-Drug Conjugates (PDCs)	Cancer
PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC₅₀ values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .

HY-160899A

Thailanstatin A cyclohexane diamine formic	Drug-Linker Conjugates for ADC	Cancer
Thailanstatin A cyclohexane diamine formic is an analog of Spliceostatin (HY-16466). Thailanstatin A cyclohexane diamine formic inhibits proliferations of cells N87 (IC₅₀ is 0.33 μM), BT474 (IC₅₀ is 0.34 μM), MDA-MB-361-DYT2 (IC₅₀ is 0.88 μM) and MDA-MB-468 (IC₅₀ is 0.27 μM). Thailanstatin A cyclohexane diamine formic is used as a drug-linker conjugate for ADC molecule .

HY-160598

Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol	ADC Payload Topoisomerase	Cancer
Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol (compound 45) is a camptothecin compound that can inhibit cell proliferation, with an IC₅₀ of 2.92 ng/mL for MDA‑MB‑468 cells. Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol can be used for the research of cancer .

HY-158377

CDK8/19-IN-2	CDK STAT	Cancer
CDK8/19-IN-2 (compound 12) is an orally active and potent cyclin-dependent kinase 8/19 (CDK8 and CDK19) inhibitor, with IC₅₀ values of 2.08 and 2.49 nM, respectively. CDK8/19-IN-2 can be used for acute myeloid leukemia (AML), breast cancer, and lymphoma research .

HY-113831

CLK1/2-IN-3	CDK SRPK	Cancer
LK1/2-IN-3 (compound 3) is a potent and selective CLK1 and CLK2 inhibitor with IC₅₀ values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs .

Cat. No.	Product Name	Type

HY-151704

ICG-alkyne

Fluorescent Dye

ICG-alkyne is a short-wave infrared (SWIR)-emitting cyanine fluorescent probe based on alkyne-derivatized indocyanine green. ICG-alkyne can undergo click chemistry reaction to conjugate with antibody molecules via binding to the azide groups introduced into antibodies. ICG-alkyne enables SWIR fluorescent molecular imaging of breast tumors in living mice. ICG-alkyne can be used in breast cancer-related research .

HY-D1236

Fluorescent brightener 71

Fluorescent Dye

Fluorescent brightener 71 (FB71) is an inhibitor targeting deubiquitinases UCHL5 and USP14, as well as a CD40 ligand. Fluorescent brightener 71 blocks enzymatic activity, induces apoptosis, inhibits cell growth and triggers reactive oxygen species production. Meanwhile, Fluorescent brightener 71 upregulates the expression of oxidative stress-related genes gpx-4 and sod-4, and reversibly increases the protein levels of UCHL5 and USP14 through a feedback response. Fluorescent brightener 71 inhibits the growth, movement and reproductive capacity of Caenorhabditis elegans, and also exhibits concentration-dependent toxic effects. Fluorescent brightener 71 can be applied to scientific research in related fields such as breast cancer .

Cat. No.	Product Name	Type

HY-NP163A

Wheat germ agglutinin-AF488

WGA-AF488

Biochemical Assay Reagents

Wheat germ agglutinin-AF488 (WGA-AF488) is a cell membrane-specific staining agent prepared by conjugating wheat germ agglutinin with the Alexa Fluor 488 (HY-D1304) fluorescent dye, and it binds to cell surface glycoproteins with high affinity. Wheat germ agglutinin-AF488 is applied in fluorescence microscopy and confocal imaging techniques, and it can clearly label the membrane structures of various cells including breast cancer cells, enabling high-resolution visual observation. Wheat germ agglutinin-AF488 is used in studies of breast cancer and triple-negative breast cancer to observe cell morphology and membrane dynamic changes .

Cat. No.	Product Name	Target	Research Area

HY-120234

Z-LLNle-CHO Z-Leu-Leu-Nle-CHO; GSII	γ-secretase Proteasome Apoptosis	Cancer
Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia .

HY-146127

Grb2 SH2 domain inhibitor 1	MEK	Cancer
Grb2 SH2 domain inhibitor 1 is an inhibitor of the Grb2 SH2 domain with an IC₅₀ of 0.40 μM. Grb2 SH2 domain inhibitor 1 is also a cell-permeable cyclic peptide that can enter the cytosol of mammalian cells. Grb2 SH2 domain inhibitor 1 downregulates the expression level of p-MEK. Grb2 SH2 domain inhibitor 1 can be used in the research of breast cancer .

HY-P10760

PhAc-ALGP-Dox	Peptide-Drug Conjugates (PDCs)	Cancer
PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC₅₀ values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .

HY-P11844

NOTA-FZCD-3	Cathepsin Radionuclide-Drug Conjugates (RDCs)	Cancer
NOTA-FZCD-3 is a NOTA (HY-134418)-labeled FZCD-3 polypeptide precursor that targets cathepsin D (CTSD) with a K_D of 0.65 μM. NOTA-FZCD-3 binds specifically to the active site of CTSD, exhibits rapid in vivo clearance properties, and remains stable in blood for more than 2 h. NOTA-FZCD-3 can be used in studies monitoring CTSD-positive tumors .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990859

Anti-CD44 Antibody (Hermes-1) 1 Publications Verification	Transmembrane Glycoprotein	Others
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a κ chimeric antibody, targeting to human CD44. Anti-CD44 Antibody (Hermes-1) blocks the binding of hyaluronan to CD44. Anti-CD44 Antibody (Hermes-1) restores (Platelet-derived Growth Factor-BB)-induced β-receptor activation and motility in fibroblasts. Anti-CD44 Antibody (Hermes-1) causes partial loss of the anti-aging effect of hyaluronic .

HY-P992488

ZV05 ZV0501 Antibody	Transmembrane Glycoprotein ADC Antibody	Cancer
ZV05 (ZV0501 Antibody) is an anti-5T4 monoclonal antibody with an EC₅₀ of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer .

HY-P991969

LR004	EGFR	Cancer
LR004 is an EGFR monoclonal antibody, with a K_d of 2.80 × 10 ^-9 M against human EGFR. LR004 shows extremely weak inhibitory effect on the viability of EGFR-positive tumor cells in vitro, but inhibits the growth of EGFR-positive tumor xenografts as a single agent. LR004 is applicable to research related to advanced colorectal cancer, solid tumors, esophageal squamous cell carcinoma, epidermoid carcinoma, colon cancer and breast cancer .

Cat. No.	Product Name		Classification

HY-115997

PROTAC HSP90 degrader BP3		PROTAC Synthesis
PROTAC HSP90 degrader BP3 is a potent and selective degradation of HSP90 in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain degradation effect on HSP90 protein in MCF-7 cells (DC₅₀=0.99 μM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell . PROTAC HSP90 degrader BP3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135699

TD52 2 Publications Verification		Alkynes
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135699A

TD52 dihydrochloride 2 Publications Verification		Alkynes
TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151704

ICG-alkyne		Alkynes
ICG-alkyne is a short-wave infrared (SWIR)-emitting cyanine fluorescent probe based on alkyne-derivatized indocyanine green. ICG-alkyne can undergo click chemistry reaction to conjugate with antibody molecules via binding to the azide groups introduced into antibodies. ICG-alkyne enables SWIR fluorescent molecular imaging of breast tumors in living mice. ICG-alkyne can be used in breast cancer-related research .

HY-157411

anti-TNBC agent-5		Alkynes
anti-TNBC agent-5 (compound 10C) is a triple-negative breast cancer (TNBC) inhibitor with good stability and pharmacokinetic properties. anti-TNBC agent-5 exhibits antiproliferative activity against a variety of cancer cells. anti-TNBC agent-5 can also effectively inhibit TNBC lung metastasis activity in the MDA-MB-231 xenograft model. anti-TNBC agent-5 can be used in cancer research .

HY-175201

pro-FTY		Azide
pro-FTY, a FTY720 (HY-12005) anticancer prodrug, is a sphingosine-1-phosphate (S1P) (HY-108496) inhibitor. pro-FTY specifically inhibits S1P signaling in cancer cells using a drug delivery system (DDS) that reacts with acrolein. pro-FTY significantly inhibits the survival of breast cancer cells, including multidrug-resistant cells and its organoids resistant to Paclitaxel (HY-B0015) or Doxorubicin (HY-15142A). pro-FTY potently suppresses tumor growth in 4T1 cells or organoids xenograft tumors mice model while avoiding lymphocytopenia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MDA-MB-468

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Natural
Products